ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
December 10, 2021 01:00 ET
|
ObsEva SA
-Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- -52-Week Data from the Phase 3...
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
May 04, 2021 01:00 ET
|
ObsEva SA
- EDELWEISS 3 trial of Yselty® expected to report topline data as planned in Q4:21- GENEVA, Switzerland and BOSTON, MA – May 4, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a...
ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis
April 22, 2020 16:30 ET
|
ObsEva SA
Significant improvement in quality of life outcomes maintained or increased after 52 weeks of treatment with linzagolixSmall, expected, non-clinically relevant increases in serum lipids...
ObsEva Provides Update Related to COVID-19 Pandemic
March 23, 2020 02:00 ET
|
ObsEva SA
Patient safety remains the top priority PRIMROSE 1 and PRIMROSE 2 trial results expected to be announced in Q2:20, as planned PROLONG trial results expected to be announced in 2H:20, as...
ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
October 11, 2019 01:00 ET
|
ObsEva SA
Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleeding from uterine fibroids while...
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe
May 09, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain
May 03, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – May 3, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and...
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain
September 28, 2018 01:00 ET
|
ObsEva SA
Linzagolix overall efficacy and safety maintained or improved at week 24 Linzagolix 75mg once daily showed no clinically significant impact on Bone Mineral Density (BMD), supporting further...